Clinical trials: Non-allergic Asthma
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house dust mite allergy over a period of 12…
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
- Trial name
- CARIOCA (NCT03746860)
- Testing
- Tablet, Dispersible
- Where
- France
- Volunteers
- 1,508 people
- Sponsor
- ALK-Abelló A/S
Asthma, Allergy
ATEM (Alvesco Non-interventional Study)
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season.
- Trial name
- ATEM (NCT01147224)
- Testing
- Alvesco
- Where
- 79 sites in Austria
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Asthma
CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids
A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild to moderate allergic asthma not sufficiently controlled on inhaled steroid.
- Trial name
- NCT02087644
- Testing
- CYT003
- Where
- United States
- Sponsor
- Cytos Biotechnology AG
Moderate to Severe Allergic Asthma
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to assess the therapeutic potential and safety/tolerability of study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to severe allergic asthma not sufficiently…
- Trial name
- NCT01673672
- Testing
- CYT003
- Where
- 34 sites in United States, Czechia and 6 more
- Volunteers
- 365 people
- Sponsor
- Cytos Biotechnology AG
Asthma, Allergy
Glasgow Asthma and Allergy Study
In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma".
- Trial name
- GLAAS (NCT01618318)
- Where
- United Kingdom
- Volunteers
- 105 people
- Sponsor
- National Services for Health Improvement Ltd
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Allergic
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
This is a multi-centre, randomized, double-blind，placebo parallel-controlled phase III study to evaluate the efficacy and safety of CMAB007 (recombinant humanized anti-immunoglobulin E(IgE) monoclonal antibody for injection) to…
- Trial name
- NCT03468790
- Testing
- CMAB007, Symbicort, Seretide
- Where
- 2 sites in China
- Volunteers
- 393 people
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Allergic Asthma
Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma
The researchers propose to study the airways of asthmatics given TPI ASM8 for 14 days, and examine the protective effects on allergen-induced bronchoconstriction, hyperresponsiveness and airway inflammation.
- Trial name
- NCT00550797
- Testing
- TPI ASM8
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Syntara
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
Tyrosine Allergoid Paediatric and Adult Study
The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial…
- Conditions
- Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma
- Trial name
- NCT05186025
- Testing
- MATA trees or MATA grass
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinitis, Rhinoconjunctivitis
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
This is an observational prospective study to assess the tolerability and safety of treatment of SCIT Allergovac Poliplus polymerized in depot presentation.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- APOLO (NCT02844842)
- Testing
- Allergovac Poliplus
- Where
- 15 sites in Spain
- Volunteers
- 152 people
- Sponsor
- Roxall Medicina España S.A